Human Reproduction, Vol. 17, No. 6, 1643-1648,
June 2002
© 2002 European Society of Human Reproduction and Embryology
Gonadotrophin stimulation reduces VEGF120 expression in the mouse uterus during the peri-implantation period
1 Division of Medical Pharmacology, Leiden/Amsterdam Center for Drug Research/Leiden University Medical Center, Gorlaeus Laboratories, P.O.Box 9502, 2300 RA Leiden and 2 Division of Reproductive Medicine, Department of Gynaecology, Leiden University Medical Center, Leiden, The Netherlands
BACKGROUND: Ovarian stimulation by gonadotrophin treatment exerts negative effects on implantation and embryonic development. We investigated whether gonadotrophin treatment affects VEGF120 mRNA expression during the peri-implantation period. METHODS: Two groups of adult female CD1 mice were used: the hormone-treated group was injected i.p. with urinary human FSH (5 IU in 0.1 ml saline) and urinary HCG (5 IU in 0.1 ml saline). Spontaneously ovulating mice served as controls and received saline injections. The pregnant mice were killed on embryonic development (ED) days 0, 3, 4, 5 and 6 (day of vaginal plug detection is considered as ED0). The uteri with the implanted embryos were processed for in-situ hybridization for VEGF120. A separate group of control and hormone-treated pregnant mice were allowed to give birth. Litter size, birthweight and length of gestational period were noted. RESULTS: Gonadotrophin treatment decreased VEGF120 mRNA levels, delayed implantation, reduced the size of the embryo implantation site on ED5 and ED6 and prolonged the gestational period. CONCLUSIONS: Gonadotrophin treatment reduces VEGF120 expression which may have serious consequences for normal embryonic development. The present data cannot establish whether this effect is a cause or consequence of delayed implantation.
Key words: gonadotrophin ovarian stimulation/peri-implantation period/VEGF120 expression
3 To whom correspondence should be addressed at: Division of Medical Pharmacology, LACDR/LUMC, Wassenaarseweg 72, 2333 AL Leiden University, The Netherlands. E-mail: r.sibug{at}lacdr.leidenuniv.nl
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  R.M. Sibug, N. Datson, A.M.I. Tijssen, M. Morsink, J. de Koning, E.R. de Kloet, and F.M. Helmerhorst Effects of urinary and recombinant gonadotrophins on gene expression profiles during the murine peri-implantation period Hum. Reprod., January 1, 2007; 22(1): 75 - 82. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Kapiteijn, C.S. de Bruijn, E. de Boer, A.J.M. de Craen, C.W. Burger, F.E. van Leeuwen, and F.M. Helmerhorst Does subfertility explain the risk of poor perinatal outcome after IVF and ovarian hyperstimulation? Hum. Reprod., December 1, 2006; 21(12): 3228 - 3234. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. L. Kelley, K. L. Kind, M. Lane, R. L. Robker, J. G. Thompson, and L. J. Edwards Recombinant human follicle-stimulating hormone alters maternal ovarian hormone concentrations and the uterus and perturbs fetal development in mice Am J Physiol Endocrinol Metab, October 1, 2006; 291(4): E761 - E770. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Edwards, K. L. Kind, D. T. Armstrong, and J. G. Thompson Effects of recombinant human follicle-stimulating hormone on embryo development in mice Am J Physiol Endocrinol Metab, May 1, 2005; 288(5): E845 - E851. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R.M. Sibug, J. de Koning, A.M.I. Tijssen, M.C. de Ruiter, E.R. de Kloet, and F.M. Helmerhorst Urinary gonadotrophins but not recombinant gonadotrophins reduce expression of VEGF120 and its receptors flt-1 and flk-1 in the mouse uterus during the peri-implantation period Hum. Reprod., March 1, 2005; 20(3): 649 - 656. [Abstract] [Full Text] [PDF]
|
|